These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 23835291)

  • 1. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.
    Lang JM; Wallace M; Becker JT; Eickhoff JC; Buehring B; Binkley N; Staab MJ; Wilding G; Liu G; Malkovsky M; McNeel DG
    Clin Genitourin Cancer; 2013 Dec; 11(4):407-15. PubMed ID: 23835291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
    Campbell SC; Bhoopalam N; Moritz TE; Pandya M; Iyer P; Vanveldhuizen P; Ellis NK; Thottapurathu L; Garewal H; Warren SR; Friedman N; Reda DJ
    Urology; 2010 May; 75(5):1138-43. PubMed ID: 20303574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid to prevent bone loss in Chinese men receiving androgen deprivation therapy for prostate cancer.
    Yee CH; Ng CF; Wong AY; Chan CK; Hou SM; Yip SK
    Asia Pac J Clin Oncol; 2011 Jun; 7(2):168-73. PubMed ID: 21585697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.
    Wadhwa VK; Weston R; Parr NJ
    BJU Int; 2010 Apr; 105(8):1082-8. PubMed ID: 19912210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
    Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
    Ryan CW; Huo D; Stallings JW; Davis RL; Beer TM; McWhorter LT
    Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term zoledronic acid during androgen blockade for prostate cancer.
    Casey R; Gesztesi Z; Rochford J
    Can J Urol; 2010 Jun; 17(3):5170-7. PubMed ID: 20566009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
    Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
    Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Titration of dosage for the protective effect of zoledronic acid on bone loss in patients submitted to androgen deprivation therapy due to prostate cancer: a prospective open-label study.
    Rodrigues P; Meler A; Hering F
    Urol Int; 2010; 85(2):180-5. PubMed ID: 20628233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
    Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
    J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
    Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).
    Wirth M; Tammela T; Cicalese V; Gomez Veiga F; Delaere K; Miller K; Tubaro A; Schulze M; Debruyne F; Huland H; Patel A; Lecouvet F; Caris C; Witjes W
    Eur Urol; 2015 Mar; 67(3):482-91. PubMed ID: 24630685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients.
    Kachnic LA; Pugh SL; Tai P; Smith M; Gore E; Shah AB; Martin AG; Kim HE; Nabid A; Lawton CA
    Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):382-6. PubMed ID: 24080992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.
    Alibhai SM; Mohamedali HZ; Gulamhusein H; Panju AH; Breunis H; Timilshina N; Fleshner N; Krahn MD; Naglie G; Tannock IF; Tomlinson G; Warde P; Duff Canning S; Cheung AM
    Osteoporos Int; 2013 Oct; 24(10):2571-9. PubMed ID: 23563932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
    J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
    Ryan CW; Huo D; Bylow K; Demers LM; Stadler WM; Henderson TO; Vogelzang NJ
    BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer.
    Panju AH; Breunis H; Cheung AM; Leach M; Fleshner N; Warde P; Duff-Canning S; Krahn M; Naglie G; Tannock I; Tomlinson G; Alibhai SM
    BJU Int; 2009 Mar; 103(6):753-7. PubMed ID: 19007370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer.
    Leal T; Tevaarwerk A; Love R; Stewart J; Binkley N; Eickhoff J; Parrot B; Mulkerin D
    Clin Breast Cancer; 2010 Dec; 10(6):471-6. PubMed ID: 21147691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.